Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bmcl.2020.127571 http://scihub22266oqcxt.onion/10.1016/j.bmcl.2020.127571 32980515!7834599!32980515     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32980515&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Bioorg+Med+Chem+Lett 2020 ; 30 (21): 127571 Nephropedia Template TP {{tp|p=32980515|t=2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor |pdf=|usr=}}{{32980515}} gab.com Text Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor JO: Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=32980515 #FOAvip NLRP3 inflammasome mediated release of interleukin-1beta (IL-1beta) has been implicated in various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea derivatives were identified as novel, potent and orally bioavailable NLRP3 inhibitors. Compound 7 was found to be potent (IL-1beta IC(50) = 35 nM; IL-18 IC(50) = 33 nM) and selective NLRP3 inflammasome inhibitor with excellent pharmacokinetic profile having oral bioavailability of 99% in mice. Twit Text FOAVip Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor ????Bioorg Med Chem Lett http://www.kidney.de/pget.php?&tw=1&pmid=32980515 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32980515 #FOAvip English Wikipedia <ref>{{Cite pmid|32980515}}</ref> Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor #MMPMID32980515 Agarwal S; Pethani JP; Shah HA; Vyas V; Sasane S; Bhavsar H; Bandyopadhyay D; Giri P; Viswanathan K; Jain MR; Sharma R Bioorg Med Chem Lett 2020[Nov]; 30 (21): 127571 PMID32980515show ga NLRP3 inflammasome mediated release of interleukin-1beta (IL-1beta) has been implicated in various diseases, including COVID-19. In this study, rationally designed alkenyl sulfonylurea derivatives were identified as novel, potent and orally bioavailable NLRP3 inhibitors. Compound 7 was found to be potent (IL-1beta IC(50) = 35 nM; IL-18 IC(50) = 33 nM) and selective NLRP3 inflammasome inhibitor with excellent pharmacokinetic profile having oral bioavailability of 99% in mice. |Administration, Oral[MESH] |Animals[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Cell Line, Tumor[MESH] |Coronavirus Infections[MESH] |Cytochrome P-450 CYP2C8 Inhibitors/administration & dosage/chemical synthesis/pharmacokinetics/pharmacology[MESH] |Cytochrome P-450 CYP2C9 Inhibitors/administration & dosage/chemical synthesis/pharmacokinetics/pharmacology[MESH] |Dogs[MESH] |Drug Stability[MESH] |Humans[MESH] |Inflammasomes/*antagonists & inhibitors[MESH] |Interleukin-1beta/antagonists & inhibitors[MESH] |Mice, Inbred C57BL[MESH] |Microsomes, Liver/metabolism[MESH] |Molecular Structure[MESH] |NLR Family, Pyrin Domain-Containing 3 Protein/*antagonists & inhibitors[MESH] |Pandemics[MESH] |Pneumonia, Viral[MESH] |Rats[MESH] |SARS-CoV-2[MESH] |Structure-Activity Relationship[MESH]Identification of a novel orally bioavailable NLRP3 inflammasome inhib(epmc).pdf DeepDyve Pubget Overpricing